1stOncology™: Cancer Intelligence Service – Page 14302 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Eleven Biotherapeutics to Present at the Cowen and Company 38th Annual Health Care Conference

On March 5, 2018 Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment , reported that the company’s management team will present at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12th at 2:50 p.m. EDT (Press release, Eleven Biotherapeutics, MAR 5, 2018, http://ir.elevenbio.com/news-releases/news-release-details/eleven-biotherapeutics-present-cowen-and-company-38th-annual [SID1234524389]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A live audio webcast of the Company’s presentation can be accessed by visiting "Events & Presentations" under the Investors & News section of Endocyte’s website at www.endocyte.com. The webcast will be archived shortly after the live event, and a replay will be available on the Company’s website for 90 days following the conference.

CymaBay Therapeutics to Participate in Upcoming Investor Conferences in March

On March 5, 2018 CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, reported that management will participate in upcoming investor conferences, including the 30th Annual ROTH Conference, the H.C. Wainwright 2nd Annual NASH Investor Event, and the Oppenheimer & Company 28th Annual Healthcare Conference (Press release, CymaBay Therapeutics, MAR 5, 2018, View Source [SID1234524388]).

30th Annual ROTH Conference 2018
Date: Monday, March 12
Time: 9am Pacific Time
Location: Ritz Carlton, Laguna Niguel, CA

H.C. Wainwright 2nd Annual NASH Investor Event
Date: Monday, March 19
Time: 9:20am Eastern Time
Location: St. Regis Hotel, New York, NY
Webcast: View Source

Oppenheimer & Company 28th Annual Healthcare Conference
Date: Tuesday, March 20
Time: 9:10am Eastern Time
Location: Westin New York Grand Hotel, NY
Webcast: View Source

8-K – Current report

On March 5, 2018 Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, reported that James Caruso, president and chief executive officer of Cellectar Biosciences, will present a company overview at the following upcoming March 2018 conferences (Filing, 8-K, Cellectar Biosciences, MAR 5, 2018, View Source [SID1234524387]):

30th Annual ROTH Conference

· Date and Time: Tuesday, March 13 at 2:30 pm PT
· Venue: The Ritz Carlton, Orange County, CA
· Webcast: View Source

28th Annual Oppenheimer Healthcare Conference

· Date and Time: Tuesday, March 20 at 4:30 pm ET
· Venue: The Westin New York Grand Central Hotel, New York, NY
· Webcast: https://www.veracast.com/webcasts/opco/healthcare2018/11117262769.cfm

A live and archived webcast of Mr. Caruso’s presentations will be available in the Events and Presentations section of the Company’s website at View Source

BioTime to Announce Fourth Quarter and Fiscal 2017 Results on March 15, 2018

On March 5, 2018 BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, reported that it will release fourth quarter and fiscal 2017 financial and operating results on Thursday, March 15, 2018, after the close of the U.S. financial markets (Press release, BioTime, MAR 5, 2018, View Source;p=RssLanding&cat=news&id=2336117 [SID1234524386]). The Company will host a conference call and webcast on Thursday, March 15, 2018, at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss the results and recent corporate developments.

The conference call dial-in number in the U.S./Canada is 1-866-888-8633. For international participants outside the U.S./Canada, the dial-in number is 1-636-812-6629. For all callers, please refer to Conference ID number 5878807. The live webcast can be accessed on the "Events & Presentations" page of the "Investors & Media" section on the company’s website.

A replay of the conference call will be available for seven business days beginning about two hours after the conclusion of the live call, by calling toll-free from U.S./Canada: 1-855-859-2056; international callers dial 1-404-537-3406. Use the Conference ID number 5878807. Additionally, the archived webcast will be available on the "Events & Presentations" page of the "Investors & Media" section on the company’s website.

Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2018 After Market Close on March 12, 2018

On March 5, 2018 Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, reported that financial results for the third quarter of fiscal year 2018 ended January 31, 2018 on March 12, 2018 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time) (Press release, Avid Bioservices, MAR 5, 2018, View Source [SID1234524385]). Avid’s senior management will discuss financial results for the third quarter and review recent corporate developments.

To listen to the live webcast, or access the archived webcast, please visit: View Source

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Avid Bioservices call.